Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Silverchair Information Systems full text link Silverchair Information Systems Free PMC article
Full text links

Actions

Share

.2012 May 1;18(9):2526-33.
doi: 10.1158/1078-0432.CCR-12-0127. Epub 2012 Mar 13.

Spleen cells from young but not old immunized mice eradicate large established cancers

Affiliations

Spleen cells from young but not old immunized mice eradicate large established cancers

Karin Schreiber et al. Clin Cancer Res..

Abstract

Purpose: Solid tumors that have grown two weeks or longer in mice and have diameters larger than 1 cm are histologically indistinguishable from autochthonous human cancers. When experimental tumors reach this clinically relevant size, they are usually refractory to most immunotherapies but may be destroyed by adoptive T-cell transfer. However, TCR-transgenic T cells and/or tumor cells overexpressing antigens are frequently used in these experiments. Here we studied the requirements for destroying clinical size, unmanipulated 8101 tumors by adoptive cell therapy.

Experimental design: 8101 arose in an old mouse after chronic exposure to UV light. A cancer line was established, which was never serially transplanted. The immunodominant CD8(+) T cell-recognized antigen of this tumor is caused by a somatic tumor-specific mutation in the RNA helicase p68. 8101 tumors were treated with spleen cells from young naive, or young and old immunized mice to ascertain the characteristics of immune cells that lead to rejection.

Results: Here we show that the mutant p68 peptide has an exceptionally high affinity to the presenting MHC class I molecule K(b) and that spleen cells from immunized young syngeneic mice adoptively transferred to Rag(-/-) or cancer-suppressed euthymic mice eradicate 8101 tumors larger than 1 cm in average diameter and established for several weeks. Spleen cells from naive young mice or from old and boosted (reimmunized) mice were ineffective.

Conclusions: Relapse-free destruction of large and long-established tumors expressing a genuine very high-affinity tumor-specific antigen can be achieved by using adoptive transfer of lymphocytes from immunized young individuals.

©2012 AACR.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cancer progressor variants are selected by young but not old naïve mice.A. Experimental design. Cryopreserved fragments of theautochthonous 8101 tumor were first adapted to culture and then injected into anude C57BL/6 mouse that developed a tumor. Fragments of this tumor weretransplanted into one old (2 year-old) and twenty young (2-3 month-old) normaleuthymic C57BL/6 mice. Five of the twenty young and the old mouse failed toreject the tumor challenge.B. Analysis of the transplant behaviorof each tumor found to be progressively growing in A by fragment transplantationinto a new set of young naïve mice. Every tumor that had developed in ayoung naïve mouse grew again, whereas the tumor that grew in the oldmouse was rejected.
Figure 2
Figure 2
Adoptive transfer of spleen cells from young immune but not naïve or oldimmune mice leads to the eradication of large established 8101 tumors inRag1-/-mice.A. Experimentaldesign.B. Tumor-bearingRag1-/-C57BL/6 mice were treated by adoptive transfer of spleen cells (one spleen perrecipient, around 1×108 cells) from young naïvedonors (3-4 month-old), young donors (3-4 month-old) immunized once with2×107 live 8101 cancer cells at the age of 2 months, orold immune mice (29 month-old) immunized when 4 month-old and boosted 2, 12 and19 months later. Results are pooled from several experiments, one of which issharing all three experimental groups and two sharing the young naïveand young immune groups. The ⊕ symbol in the right panel designates atumor that was reisolated and found to express the mutant p68 gene byRT-PCR. * The average tumor size and duration of growth of 8101 (mean ±SD) at time of treatment was: 1117 ± 339 mm3 and 41 ±11 d for the “naïve young” group; 1219 ± 315mm3 and 39 ± 7 d for the “young immune”;1203 ± 961 mm3 and 30 ± 6 d for the “oldimmune”.
Figure 3
Figure 3
Adoptive transfer of spleen cells from young immune but not naïve or oldimmune mice leads to the eradication of large 8101 tumors grown in euthymicB6C3F1 mice.A. Experimental design.B. 8101-bearingeuthymic B6C3F1 mice were treated by adoptive transfer of spleen cells (onespleen per recipient, around 1×108 cells) from youngnaïve donors (3-4 month-old), young donors (4-8 month-old) immunizedonce with 2×107 live 8101 cancer cells 2 months beforetransfer, or old immune mice (9-16 month-old) immunized when 2-3 month-old andboosted 2 months before transfer. Results are pooled from several experiments,one sharing all three experimental groups and two sharing the youngnaïve and young immune group. The ⊕ symbols in the right andleft panels designate tumors that were reisolated and found to express themutant p68 gene by RT-PCR; the antigen-loss variant is designated withØ.a The pre-existent PRO4L tumor burden at time of 8101 inoculation was539 ± 165 mm3 (mean ± SD) and had grown for anaverage of 21 ± 8 days.b The average size of PRO4L was 1577 ± 988 mm3 whenstrung at day 38 ± 10 of growth 8101 had grown for an average of 18± 10 days when the PRO4L tumor burden was removed.c The average tumor size and duration of growth of 8101 at time oftreatment was: 738 ± 206 mm3 and 19 ± 6 d for the“naïve young” group; 845 ± 328 mm3and 29 ± 9 d for the “young immune”; 909 ± 286mm3 and 28 ± 19 d for the “oldimmune”.
Figure 4
Figure 4
Old and young mice have similar numbers of mp68-specific CD8+T cells but differ in number of CD4+ T cells and in theability to increase the percentage of effector memory cells after boosting.A. Peripheral blood cells were isolated from naïve andimmune young or old mice (5 mice per group) and the binding of mp68peptide-loaded tetramers to CD8+ T cells was measured. Theyoung (6 month-old) immune mice had been primed once at the age of 2 monthswhereas the old (16 month-old) immune mice had been primed at 2 months of ageand boosted at 5 and 12 months of age. Day 0 of analysis corresponds to 4 monthsafter immunization/last boosting respectively. The results are representativefor 3 mice each, for young and old. M-mp68 is a cell line transfected to expressvery high levels of mp68 antigen.B. Absolute numbers ofCD4+ and CD8+ T cells were determinedin peripheral blood from old (14 month-old) and young (4 month-old) mice. Anexperiment representative of two is shown with data from 5 mice per group.C. The percentages of central memory (CM:CD62Lhi/CD44hi), and effector memory (EM:CD62Llo/CD44hi) CD8+ T cells weredetermined in peripheral blood from old (16 month-old) and young (6 month-old)mice before (pre) and on day 9 after boosting (post) as in A. 4-5 mice per groupwere analyzed in total in two experiments pooled here. *p <0.05; **p ≤ 0.01; ns, no significant.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Stricker TP, Kumar V. Neoplasia. In: Kumar V, Abbas AK, Fausto N, Aster J, editors. Robbins & Cotran Pathologic Basis of Disease. 8. Philadelphia: WB Saunders; 2009.
    1. Wen FT, Thisted RA, Rowley DA, Schreiber H. A systematic analysis of experimental immunotherapies on tumors differing in size and durationof growth. Oncoimmunology. 2012;1:172–178. - PMC - PubMed
    1. Spiotto MT, Rowley DA, Schreiber H. Bystander elimination of antigen loss variants in established tumors. Nat Med. 2004;10:294–8. - PubMed
    1. Garcia-Hernandez Mde L, Hamada H, Reome JB, Misra SK, Tighe MP, Dutton RW. Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice. J Immunol. 2010;184:4215–27. - PMC - PubMed
    1. Anders K, Buschow C, Herrmann A, Milojkovic A, Loddenkemper C, Kammertoens T, et al. Oncogene-Targeting T Cells Reject Large Tumors while Oncogene Inactivation Selects Escape Variants in Mouse Models of Cancer. Cancer Cell. 2011;20:755–67. - PMC - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full text links
Silverchair Information Systems full text link Silverchair Information Systems Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp